Business Description
Molecular Templates Inc
NAICS : 325414
SIC : 2836
ISIN : US6085501095
Description
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.15 | |||||
| Equity-to-Asset | 0.27 | |||||
| Debt-to-Equity | 1.18 | |||||
| Debt-to-EBITDA | -0.79 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -24.98 | |||||
| Beneish M-Score | 2.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 33.4 | |||||
| 3-Year EPS without NRI Growth Rate | 56.6 | |||||
| 3-Year FCF Growth Rate | 31.2 | |||||
| 3-Year Book Growth Rate | -64.7 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 12-1 Month Momentum % | 6.04 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.56 | |||||
| Quick Ratio | 1.56 | |||||
| Cash Ratio | 1.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.3 | |||||
| Shareholder Yield % | 15415.91 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -80.28 | |||||
| Net Margin % | -66.54 | |||||
| FCF Margin % | -102.26 | |||||
| ROE % | -510.12 | |||||
| ROA % | -46.29 | |||||
| ROIC % | -64.32 | |||||
| ROC (Joel Greenblatt) % | -92.9 | |||||
| ROCE % | -89.33 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 0.01 | |||||
| PB Ratio | 0.03 | |||||
| Price-to-Tangible-Book | 0.03 | |||||
| EV-to-EBIT | 0.07 | |||||
| EV-to-EBITDA | 0.1 | |||||
| EV-to-Revenue | -0.05 | |||||
| EV-to-Forward-Revenue | 1.27 | |||||
| EV-to-FCF | 0.04 | |||||
| Earnings Yield (Greenblatt) % | 1428.57 | |||||
| FCF Yield % | -12082.83 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Molecular Templates Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 21.685 | ||
| EPS (TTM) (€) | -0.768 | ||
| Beta | 0 | ||
| Volatility % | 45.16 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 7.95 | ||
| 12-1 Month Momentum % | 6.04 | ||
| 52-Week Range (€) | 3.863999 - 10.514999 | ||
| Shares Outstanding (Mil) | 5.37 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Molecular Templates Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Molecular Templates Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Molecular Templates Inc Frequently Asked Questions
What is Molecular Templates Inc(FRA:NZW)'s stock price today?
The current price of FRA:NZW is €7.95. The 52 week high of FRA:NZW is €10.51 and 52 week low is €3.86.
When is next earnings date of Molecular Templates Inc(FRA:NZW)?
The next earnings date of Molecular Templates Inc(FRA:NZW) is 2025-03-28 Est..
Does Molecular Templates Inc(FRA:NZW) pay dividends? If so, how much?
Molecular Templates Inc(FRA:NZW) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers